FDA signs off on Ot­su­ka, Lund­beck­'s an­tipsy­chot­ic for Alzheimer's ag­i­ta­tion

The FDA has ap­proved Ot­su­ka and Lund­beck’s an­tip­sy­chot­ic Rex­ul­ti for ag­i­ta­tion as­so­ci­at­ed with de­men­tia due to Alzheimer’s dis­ease, bring­ing to mar­ket the first ther­a­py de­signed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER